4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 94 | 100 | +6 |
| Shares | 30.4M | 41.2M | +10.8M (+35.7%) |
| Value | $522.3M | $745.3M | +$223.0M (+42.7%) |
New holders (22)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ra Capital Management, L.P. | 3,069,531 | $55.5M | 1.05% |
| VR Adviser, LLC | 3,000,000 | $54.2M | 8.67% |
| Deerfield Management Company, L.P. (Series C) | 650,000 | $11.7M | 0.25% |
| Great Point Partners LLC | 350,000 | $6.32M | 1.27% |
| Millennium Management LLC | 278,701 | $5.04M | 0.01% |
| Invesco Ltd. | 215,576 | $3.90M | 0.00% |
| First Manhattan Co | 144,492 | $2.61M | 0.01% |
| Verition Fund Management LLC | 72,709 | $1.31M | 0.02% |
| EcoR1 Capital, LLC | 66,978 | $1.21M | 0.03% |
| Blackstone Group Inc. | 50,000 | $903.5K | 0.00% |
| Bellevue Group AG | 45,000 | $813.1K | 0.01% |
| Jane Street Group, LLC | 41,783 | $755.0K | 0.00% |
| Ergoteles LLC | 35,922 | $649.1K | 0.03% |
| Ghisallo Capital Management LLC | 25,000 | $451.8K | 0.05% |
| Elmwood Wealth Management, Inc. | 19,800 | $357.8K | 0.17% |
| Franklin Resources Inc | 14,416 | $260.5K | 0.00% |
| Caption Management, LLC | 11,944 | $215.8K | 0.04% |
| Sandia Investment Management LP | 7,500 | $135.5K | 0.04% |
| Itau Unibanco Holding S.A. | 1,133 | $20.5K | 0.00% |
| US Bancorp | 264 | $4.77K | 0.00% |
| Impact Partnership Wealth, LLC | 57 | $1.03K | 0.00% |
| Signaturefd, LLC | 22 | $398 | 0.00% |
Sold out (16)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Octagon Capital Advisors LP | 499,996 | $8.59M |
| Norges Bank | 294,000 | $5.05M |
| Acuta Capital Partners, LLC | 104,753 | $1.80M |
| D. E. Shaw & Co., Inc. | 81,457 | $1.40M |
| Vontobel Holding Ltd. | 80,529 | $1.38M |
| Sectoral Asset Management Inc | 80,029 | $1.38M |
| Marshall Wace, LLP | 33,954 | $583.7K |
| Laurion Capital Management LP | 21,401 | $367.9K |
| Algert Global LLC | 16,410 | $282.1K |
| Peloton Wealth Strategists | 16,000 | $275.0K |
| Renaissance Technologies LLC | 13,800 | $237.0K |
| PDT Partners, LLC | 10,795 | $185.6K |
| SG Americas Securities, LLC | 6,275 | $108.0K |
| Denali Advisors LLC | 2,000 | $34.4K |
| TCI Wealth Advisors, Inc. | 187 | $3.21K |
| Crewe Advisors LLC | 142 | $2.44K |